Can-Fite BioPharma’s Phase 3 Psoriasis Study: A Potential Game Changer?

Can-Fite BioPharma Ltd ((CANF)) announced an update on their ongoing clinical study.

Can-Fite BioPharma Ltd is conducting a Phase 3 study titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Daily Piclidenoson (CF101) Administered Orally in Subjects With Moderate-to-Severe Plaque Psoriasis.’ The study aims to evaluate the safety and efficacy of piclidenoson, a drug designed to treat moderate-to-severe plaque psoriasis, a chronic skin condition.

The intervention being tested is piclidenoson, a selective A3AR agonist administered orally in tablet form. The study also includes a placebo group for comparison.

This interventional study is randomized and employs a parallel assignment model. It is double-blind, meaning that participants, care providers, investigators, and outcomes assessors are unaware of the treatment assignments. The primary purpose of the study is treatment-focused, with an interim analysis planned to assess futility.

The study was first submitted on October 9, 2024, with the latest update submitted on April 28, 2025. Recruitment has not yet begun, indicating that the study is still in its early stages.

The market implications of this study are significant for Can-Fite BioPharma Ltd, as positive results could enhance investor confidence and potentially boost stock performance. The study’s progress will be closely watched by investors and competitors in the pharmaceutical industry, particularly those focusing on psoriasis treatments.

The study is ongoing, with further details available on the ClinicalTrials portal.